Our research approach is the following:

  • Perform a randomized, placebo-controlled, international multicentre, parallel study of AZD0328 for the treatment of PD-MCI.
  • To collect, manage and analyse data from Cog Pro as a primary outcome measure and other clinical aspects (cognition, motor symptoms) as secondary outcomes.
  • To assess blood-based biomarkers and imaging biomarkers as potential predictors of response, and as marker of target involvement.
Share this page…